PAOG Takes CBD Pharmaceutical Research Global To Target $5.8 Billion Market
September 15 2020 - 9:54AM
InvestorsHub NewsWire
Sandusky, OH -- September 15, 2020 --
InvestorsHub NewsWire -- PAO Group, Inc. (USOTC:
PAOG) Announces a multifold, international research initiative
to advance its hemp derived cannabidiol (CBD) pharmaceutical
treatment for Chronic Obstructive Pulmonary Disease
(COPD).
The COPD treatment, RespRx, is derived
from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled “METHOD AND
APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE
CANNABIS PLANT.”
In an initial scientific evaluation as a
treatment for COPD, RespRx has demonstrated effecting significant
increases in respiration rate, tidal volume and inspiratory air
flow rate. Overall data from the evaluation demonstrated that
RespRx can significantly improve inspiratory lung functions in
instances of moderate pulmonary
fibrosis.
This Friday, September 18, 2020, PAOG CEO
James C. DiPrima will discuss in an
interview with Donald Baillargeon of MoneyTV, PAOG’s multifold
international approach to engaging a Contract Research
Organization (CRO) to advance an Investigational New Drug Application
(IND) to ultimately achieve Food and Drug
Administration (FDA) approval for PAOG’s
RespRx as a COPD treatment.
Grand View Research projects that the cannabis
pharmaceutical market will reach a size of $5.8 billion by
2027.
On Friday, DiPrima will also discuss the recently
published Goldman Small
Cap Analyst Research Update on PAOG that
includes target pricing.
www.paogroupinc.com
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Aug 2024 to Sep 2024
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Sep 2023 to Sep 2024